Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Prolia Policy Update | OpenPa…
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Osteoporosis Agents: Prolia and Denosumab Biosimilars

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Prolia and denosumab biosimilars under the MassHealth medical benefit for osteoporosis, glucocorticoid-induced osteoporosis, and bone-mass preservation during selected high-risk cancer therapies. Clinical documentation, preferred-product sequencing, and renewal criteria apply.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyOsteoporosis Agents: Prolia and Denosumab Biosimilars
    Policy CodePolicy N/A
    Change TypeAdded preferred biosimilar
    Effective DateJanuary 4, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionFor non-preferred products, document inadequate response, adverse reaction, or contraindication to Bildyos, Enoby, and Osvyrti, plus clinical rationale for a different expected clinical outcome.
    SourceLink
    POLICY UPDATE CHANGES

    Osvyrti (denosumab-desu) was added as an additional preferred denosumab biosimilar and requires prior authorization through both the pharmacy and medical benefits.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 year
    Authorization duration
    90 daysNew-plan-member lookback
    3Preferred denosumab biosimilars
    >5 mg / 3 moChronic glucocorticoid threshold
    T-score < -3.0Very-high-fracture-risk threshold

    Covered Indications

    Treatment or prevention of osteoporosis

    Covered for treatment or prevention of osteoporosis when all of the following are met.

    Required criteria

    • Osteoporosis indication

      • The member has an indication for treatment or prevention of osteoporosis.
    • Bisphosphonate history or very high fracture risk

      • The member has inadequate response to an adequate trial or an adverse reaction to one oral bisphosphonate.
      • The member is contraindicated to all oral bisphosphonates.
      • Very-high-fracture-risk finding

        • History of fracture within the past 12 months.
        • History of fractures while on osteoporosis therapy.
        • History of multiple fractures.
        • History of fractures while taking drugs causing skeletal harm, such as long-term glucocorticoids.
        • T-score less than -3.0.T-score < -3.0
        • High risk for falls.
        • History of injurious falls.
    • Requested product pathway

      • The requested product is Bildyos, Enoby, or Osvyrti.
      • Non-preferred product requirements

        • For Bosaya, Conexxence, Jubbonti, Ospomyv, Prolia, or Stoboclo, the member has inadequate response, an adverse reaction, or a contraindication to all of Bildyos, Enoby, and Osvyrti.
        • The prescriber provides clinical rationale explaining why the requested non-preferred agent is expected to provide a different clinical outcome than the preferred agents.
    • Ospomyv additional requirement

      • For Ospomyv, the prescriber submits documentation of trials of alternatives with rebate or clinical rationale for use of a non-rebate product.

    Treatment or prevention of glucocorticoid-induced osteoporosis

    Covered for treatment or prevention of glucocorticoid-induced osteoporosis when all of the following are met.

    Required criteria

    • Glucocorticoid-induced osteoporosis indication or exposure

      • The member has an indication for treatment or prevention of glucocorticoid-induced osteoporosis.
      • The member has chronic glucocorticoid use determined by paid claims for more than 5 mg of prednisone equivalent for at least 3 months.>5 mg prednisone equivalent for ≥3 months
    • Bisphosphonate history or very high fracture risk

      • The member has inadequate response to an adequate trial or an adverse reaction to one oral bisphosphonate.

    Bone-mass increase during qualifying cancer therapy

    Covered for increasing bone mass in a high-risk member receiving qualifying cancer therapy when all of the following are met.

    Required criteria

    • Qualifying oncology indication

      • The member is receiving adjuvant aromatase inhibitor therapy for breast cancer and is at high risk for fracture.
      • The member is receiving androgen deprivation therapy for non-metastatic prostate cancer and is at high risk for fracture.
    • Bisphosphonate history or contraindication

      • The member has inadequate response to an adequate trial or an adverse reaction to one bisphosphonate.
      • The member is contraindicated to all oral and injectable bisphosphonates.

    Clinical Thresholds and Lookback Rules

    Very-high-fracture-risk bone density
    ThresholdT-score less than -3.0
    Clinical useQualifies as a very-high-fracture-risk finding.
    Assessment typeBone mineral density score.
    Chronic glucocorticoid use
    Dose threshold>5 mg of prednisone equivalent
    DurationAt least 3 months
    Evidence sourcePaid claims history

    Authorization and Documentation Requirements

    Prior Authorization

    Medical-Benefit Prior Authorization Required

    Prior authorization is required under the MassHealth medical benefit for the listed osteoporosis agents. These medications may also be available under the pharmacy benefit; consult the MassHealth Drug List for pharmacy coverage and criteria.

    • Affected agents include Prolia, Bildyos, Bosaya, Conexxence, Enoby, Jubbonti, Ospomyv, Osvyrti, and Stoboclo.
    • Medical Benefit phone: 833-895-2611; fax: 888-656-6671.
    Step Therapy

    Preferred Denosumab Biosimilar Step Therapy

    For a non-preferred denosumab product, document inadequate response, an adverse reaction, or a contraindication to all required preferred biosimilars before requesting authorization.

    • Required preferred biosimilars: Bildyos (denosumab-nxxp), Enoby (denosumab-qbde), and Osvyrti (denosumab-desu).
    • Applies to Bosaya, Conexxence, Jubbonti, Ospomyv, Prolia, and Stoboclo.

    Clinical Background

    Prolia (denosumab) is a biologic monoclonal antibody used to treat or prevent osteoporosis and glucocorticoid-induced osteoporosis in men and women at high risk for fracture. High risk may be established by a history of osteoporotic fracture, multiple fracture-risk factors, or failure or intolerance of other available osteoporosis therapy.

    Clinical Definitions

    FRAX
    DefinitionA validated fracture-risk assessment tool or other validated fracture-risk algorithm.
    PurposeUsed to establish very high fracture probability.
    Policy roleVery high fracture probability by FRAX or another validated algorithm is a qualifying very-high-fracture-risk finding.
    T-score
    DefinitionBone mineral density score.
    ThresholdLess than -3.0
    Policy roleQualifies as one of the policy's very-high-fracture-risk findings.

    Initial Therapy

    Initial osteoporosis therapy

    Initial therapy for osteoporosis treatment or prevention requires all of the following.

    Required criteria

    • The member has an indication for treatment or prevention of osteoporosis.
    • Bisphosphonate or fracture-risk criterion

      • The member has inadequate response to an adequate trial or an adverse reaction to one oral bisphosphonate.
      • The member is contraindicated to all oral bisphosphonates.
      • Very-high-fracture-risk feature

    Continuation Therapy

    Continuation therapy

    Continuation authorization may be granted when one of the following pathways is met.

    Continuation pathway

    • The prescriber resubmits the request, which infers positive response to therapy.
    • Preferred biosimilar continuation

      • The member is stabilized on Bildyos and Enoby.
      • Medical records document that the member remains at high risk for fracture or has a clinical picture suggesting high risk for fracture.
    • Continuation of Prolia or another denosumab biosimilar

    Preferred Biosimilar Sequencing

    StepPreferred denosumab biosimilarsNon-preferred productsRequirement
    1Bildyos (denosumab-nxxp); Enoby (denosumab-qbde); Osvyrti (denosumab-desu)Bosaya (denosumab-kyqq); Conexxence (denosumab-bnht); Jubbonti (denosumab-bbdz); Ospomyv (denosumab-dssb); Prolia (denosumab); Stoboclo (denosumab-bmwo)Before requesting a non-preferred product, document inadequate response, an adverse reaction, or a contraindication to all three preferred biosimilars and provide clinical rationale explaining why the requested agent is expected to produce a different clinical outcome.

    Preferred Denosumab Biosimilars

    Billing Rule

    Bildyos is preferred

    Bildyos (denosumab-nxxp) is a preferred denosumab biosimilar for Prolia (denosumab).

    Billing Rule

    Enoby is preferred and part of required sequencing

    Enoby (denosumab-qbde) is a preferred denosumab biosimilar for Prolia (denosumab) and is one of the preferred products that must be addressed before requesting a non-preferred product.

    • Non-preferred products require inadequate response, an adverse reaction, or a contraindication to Bildyos, Enoby, and Osvyrti.
    • Clinical rationale for a different expected clinical outcome is also required.
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyOsteoporosis Agents: Prolia and Denosumab Biosimilars
    Policy CodePolicy N/A
    Change TypeAdded preferred biosimilar
    Effective DateJanuary 4, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionFor non-preferred products, document inadequate response, adverse reaction, or contraindication to Bildyos, Enoby, and Osvyrti, plus clinical rationale for a different expected clinical outcome.
    SourceLink
    On This Page
    Covered IndicationsClinical Thresholds and Lookback RulesAuthorization and Documentation RequirementsClinical BackgroundClinical DefinitionsInitial TherapyContinuation TherapyPreferred Biosimilar SequencingPreferred Denosumab Biosimilars
  1. Very high fracture probability by FRAX or another validated fracture-risk algorithm.
  2. The member is contraindicated to oral bisphosphonates.
  3. Very-high-fracture-risk finding

    • History of fracture within the past 12 months.
    • History of fractures while on osteoporosis therapy.
    • History of multiple fractures.
    • History of fractures while taking drugs causing skeletal harm, such as long-term glucocorticoids.
    • T-score less than -3.0.T-score < -3.0
    • High risk for falls.
    • History of injurious falls.
    • Very high fracture probability by FRAX or another validated fracture-risk algorithm.
  4. Requested product pathway

    • The requested product is Bildyos, Enoby, or Osvyrti.
    • Non-preferred product requirements

      • For Bosaya, Conexxence, Jubbonti, Ospomyv, Prolia, or Stoboclo, the member has inadequate response, an adverse reaction, or a contraindication to all of Bildyos, Enoby, and Osvyrti.
      • The prescriber provides clinical rationale explaining why the requested non-preferred agent is expected to provide a different clinical outcome than the preferred agents.
  5. Ospomyv additional requirement

    • For Ospomyv, the prescriber submits documentation of trials of alternatives with rebate or clinical rationale for use of a non-rebate product.
  6. Requested product pathway

    • The requested product is Bildyos, Enoby, or Osvyrti.
    • Non-preferred product requirements

      • For Bosaya, Conexxence, Jubbonti, Ospomyv, Prolia, or Stoboclo, the member has inadequate response, an adverse reaction, or a contraindication to all of Bildyos, Enoby, and Osvyrti.
      • The prescriber provides clinical rationale explaining why the requested non-preferred agent is expected to provide a different clinical outcome than the preferred agents.
  7. Ospomyv additional requirement

    • For Ospomyv, the prescriber submits documentation of trials of alternatives with rebate or clinical rationale for use of a non-rebate product.
  8. Recent fracture
    Qualifying eventHistory of fracture within the past 12 months
    Risk categoryVery-high-fracture-risk finding
    Applicable indicationsOsteoporosis or glucocorticoid-induced osteoporosis
    New-plan-member treatment lookback
    Lookback periodCoverage effective date less than or equal to 90 days
    Required documentationMedical records documenting that the member is currently receiving treatment with the requested drug
    Excluded sources of treatmentSamples or manufacturer patient assistance programs do not qualify.
  9. Also submit clinical rationale explaining why the requested non-preferred agent is expected to provide a different clinical outcome than the preferred agents.
  10. Documentation Required

    New-Plan-Member Current-Treatment Records

    For members whose coverage became effective within the past 90 days, submit medical records showing that the member is currently receiving the requested drug. Do not use samples or manufacturer patient assistance programs as evidence of current treatment.

    • Coverage effective date must be less than or equal to 90 days.
    • Include records documenting current treatment with the requested product.
    Documentation Required

    Clinical History and Fracture-Risk Documentation

    Submit a complete clinical history supporting the applicable indication and prior treatment requirements, including bisphosphonate outcomes or intolerance, contraindications, and qualifying fracture-risk findings.

    • Document inadequate response to an adequate trial or an adverse reaction to the required oral or injectable bisphosphonate, or the applicable contraindication.
    • When relying on very high fracture risk, document at least one qualifying finding: fracture within the past 12 months; fractures while on osteoporosis therapy; multiple fractures; fractures while taking drugs causing skeletal harm; T-score less than -3.0; high risk for falls; injurious falls; or very high FRAX or other validated fracture-risk probability.
    • For oncology-related therapy, document the applicable bisphosphonate trial, adverse reaction, or contraindication.
    Documentation Required

    Non-Preferred Biosimilar Rationale

    For a non-preferred product, provide documentation of inadequate response, an adverse reaction, or a contraindication to Bildyos, Enoby, and Osvyrti, together with clinical rationale for the requested product.

    • The requirement applies to Bosaya, Conexxence, Jubbonti, Ospomyv, Prolia, and Stoboclo.
    • Documentation must address all three preferred biosimilars.
    • Explain why the requested non-preferred agent is expected to provide a different clinical outcome.
    Documentation Required

    Ospomyv Rebate-Alternative Documentation

    For Ospomyv, submit documentation that the member meets the applicable clinical criteria and that rebate alternatives were tried, or provide clinical rationale for using a non-rebate product.

    • Document trials of alternatives with rebate when applicable.
    • If rebate alternatives were not tried, provide a clinical rationale supporting use of Ospomyv as a non-rebate product.
    Documentation Required

    Continuation Fracture-Risk Records

    For continuation requests, document that the member remains at high fracture risk or has a clinical picture supporting continued treatment, as applicable to the requested product.

    • For members stabilized on Bildyos and Enoby, submit records showing continued high fracture risk or a clinical picture suggesting high fracture risk.
    • For members stabilized on Prolia or another denosumab biosimilar other than Bildyos and Enoby, submit records showing continued high fracture risk or a clinical picture suggesting high fracture risk.
    • For the latter group, also provide clinical rationale for using the requested agent instead of Bildyos and Enoby.
    Denial Risk

    Insufficient Osteoporosis Criteria

    Authorization may be denied when the osteoporosis indication, required bisphosphonate failure or intolerance, or applicable oral bisphosphonate contraindication is not documented.

    • Document treatment or prevention of osteoporosis.
    • Document inadequate response to an adequate trial or an adverse reaction to one oral bisphosphonate, or contraindication to all oral bisphosphonates.
    • Alternatively, document at least one qualifying very-high-fracture-risk finding.
    Denial Risk

    Insufficient Glucocorticoid-Induced Osteoporosis Criteria

    Authorization may be denied when the glucocorticoid-induced osteoporosis indication or qualifying chronic glucocorticoid use is not documented, or when the required treatment history or fracture-risk criteria are absent.

    • Document treatment or prevention of glucocorticoid-induced osteoporosis, or claims-supported chronic use of more than 5 mg prednisone equivalent for at least 3 months in paid claims history.
    • Also document the required bisphosphonate response, adverse reaction, or contraindication, or a qualifying very-high-fracture-risk finding.
    Denial Risk

    Insufficient Oncology-Related Indication

    Authorization may be denied when a qualifying oncology-related indication is not documented.

    • Document that the member is at high risk for fracture and is receiving adjuvant aromatase inhibitor therapy for breast cancer, or androgen deprivation therapy for non-metastatic prostate cancer.
    • Also document the required bisphosphonate inadequate response, adverse reaction, or contraindication.
    Denial Risk

    Non-Preferred Product Sequencing Not Met

    Authorization may be denied when required sequencing documentation for a non-preferred denosumab product is absent.

    • Document inadequate response, adverse reaction, or contraindication to each of Bildyos, Enoby, and Osvyrti.
    • Include clinical rationale explaining why the requested non-preferred product is expected to provide a different clinical outcome.
    Denial Risk

    Ospomyv Non-Rebate Justification Missing

    Authorization for Ospomyv may be denied when documentation of rebate-alternative trials or clinical rationale for a non-rebate product is missing.

    • Submit trials of alternatives with rebate, or explain clinically why a non-rebate product is required.
    • The member must also meet the applicable underlying clinical criteria.
    Denial Risk

    Continuation Criteria Not Met

    Continuation authorization may be denied when positive response, stabilization, ongoing high fracture risk, or the required clinical rationale is not established.

    • A prescriber resubmission infers positive response to therapy; otherwise document the applicable continuation criteria.
    • For members stabilized on Bildyos and Enoby, document ongoing high fracture risk or a clinical picture suggesting high fracture risk.
    • For members stabilized on Prolia or another denosumab biosimilar other than Bildyos and Enoby, document ongoing high fracture risk or a supporting clinical picture and provide rationale for using the requested agent instead of Bildyos and Enoby.
    History of fracture within the past 12 months.
  11. History of fractures while on osteoporosis therapy.
  12. History of multiple fractures.
  13. History of fractures while taking drugs causing skeletal harm, such as long-term glucocorticoids.
  14. T-score less than -3.0.T-score < -3.0
  15. High risk for falls.
  16. History of injurious falls.
  17. Very high fracture probability by FRAX or another validated fracture-risk algorithm.
  18. Non-preferred product criteria

    • The member has inadequate response, an adverse reaction, or a contraindication to all of Bildyos, Enoby, and Osvyrti.
    • The prescriber provides clinical rationale explaining why the requested agent is expected to provide a different clinical outcome than the preferred agents.
  19. Ospomyv additional criteria

    • The prescriber submits documentation of trials of alternatives with rebate or clinical rationale for use of a non-rebate product.
  20. Initial glucocorticoid-induced osteoporosis therapy

    Initial therapy for glucocorticoid-induced osteoporosis requires all of the following.

    Required criteria

    • Glucocorticoid indication or exposure

      • The member has an indication for treatment or prevention of glucocorticoid-induced osteoporosis.
      • The member has chronic glucocorticoid use determined by paid claims for more than 5 mg of prednisone equivalent for at least 3 months.>5 mg prednisone equivalent for ≥3 months
    • Bisphosphonate or fracture-risk criterion

      • The member has inadequate response to an adequate trial or an adverse reaction to one oral bisphosphonate.
      • The member is contraindicated to oral bisphosphonates.
      • Very-high-fracture-risk feature

        • History of fracture within the past 12 months.
        • History of fractures while on osteoporosis therapy.
        • History of multiple fractures.
        • History of fractures while taking drugs causing skeletal harm, such as long-term glucocorticoids.
        • T-score less than -3.0.T-score < -3.0
        • High risk for falls.
    • Non-preferred product criteria

      • The member has inadequate response, an adverse reaction, or a contraindication to all of Bildyos, Enoby, and Osvyrti.
      • The prescriber provides clinical rationale explaining why the requested agent is expected to provide a different clinical outcome than the preferred agents.
    • Ospomyv additional criteria

      • The prescriber submits documentation of trials of alternatives with rebate or clinical rationale for use of a non-rebate product.

    Initial oncology-related bone-mass therapy

    Initial therapy for oncology-related bone-mass increase requires all of the following.

    Required criteria

    • Qualifying cancer therapy

      • The member is at high risk for fracture while receiving adjuvant aromatase inhibitor therapy for breast cancer.
      • The member is at high risk for fracture while receiving androgen deprivation therapy for non-metastatic prostate cancer.
    • Bisphosphonate criterion

      • The member has inadequate response to an adequate trial or an adverse reaction to one bisphosphonate.
      • The member is contraindicated to all oral and injectable bisphosphonates.
    • Non-preferred product criteria

      • The member has inadequate response, an adverse reaction, or a contraindication to all of Bildyos, Enoby, and Osvyrti.
      • The prescriber provides clinical rationale explaining why the requested agent is expected to provide a different clinical outcome than the preferred agents.
    • Ospomyv additional criteria

      • The prescriber submits documentation of trials of alternatives with rebate or clinical rationale for use of a non-rebate product.
    The member is stabilized on Prolia or another denosumab biosimilar, except Bildyos and Enoby.
  21. Medical records document that the member remains at high risk for fracture or has a clinical picture suggesting high risk for fracture.
  22. The prescriber provides clinical rationale for use of the requested agent instead of Bildyos and Enoby.
  23. Billing Rule

    Osvyrti becomes preferred January 4, 2027

    Osvyrti (denosumab-desu) is an additional preferred denosumab biosimilar effective January 4, 2027. It must be included in the preferred-product sequencing before requesting a non-preferred product.

    History of injurious falls.
  24. Very high fracture probability by FRAX or another validated fracture-risk algorithm.